CA3164979A1 - New polypeptide complex - Google Patents

New polypeptide complex

Info

Publication number
CA3164979A1
CA3164979A1 CA3164979A CA3164979A CA3164979A1 CA 3164979 A1 CA3164979 A1 CA 3164979A1 CA 3164979 A CA3164979 A CA 3164979A CA 3164979 A CA3164979 A CA 3164979A CA 3164979 A1 CA3164979 A1 CA 3164979A1
Authority
CA
Canada
Prior art keywords
chain
seq
obscurin
titin
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3164979A
Other languages
English (en)
French (fr)
Inventor
Hua Ying
Qiyue Hu
Ling Zhang
Langyong MAO
Jinping SHI
Tingting Li
Weiming Lai
Qianshan QIN
Xinsheng JIN
Weikang Tao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CA3164979A1 publication Critical patent/CA3164979A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3164979A 2020-01-09 2021-01-08 New polypeptide complex Pending CA3164979A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010020878 2020-01-09
CN202010020878.7 2020-01-09
PCT/CN2021/070832 WO2021139758A1 (zh) 2020-01-09 2021-01-08 新型多肽复合物

Publications (1)

Publication Number Publication Date
CA3164979A1 true CA3164979A1 (en) 2021-07-15

Family

ID=76787741

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3164979A Pending CA3164979A1 (en) 2020-01-09 2021-01-08 New polypeptide complex

Country Status (9)

Country Link
US (1) US20230120270A1 (cg-RX-API-DMAC7.html)
EP (1) EP4089111A4 (cg-RX-API-DMAC7.html)
JP (1) JP7773981B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220123072A (cg-RX-API-DMAC7.html)
CN (1) CN114746440B (cg-RX-API-DMAC7.html)
AU (1) AU2021205561A1 (cg-RX-API-DMAC7.html)
CA (1) CA3164979A1 (cg-RX-API-DMAC7.html)
TW (1) TWI878430B (cg-RX-API-DMAC7.html)
WO (1) WO2021139758A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4372001A4 (en) * 2021-07-14 2025-02-12 Jiangsu Hengrui Pharmaceuticals Co., Ltd. ANTIGEN-BINDING MOLECULE SPECIFICALLY BINDING TO HGFR AND EGFR, AND PHARMACEUTICAL USE THEREOF

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI917325B (zh) 2019-06-04 2026-03-11 大陸商江蘇恆瑞醫藥股份有限公司 能結合胸腺基質淋巴細胞生成素的抗體及其應用
MX2023006596A (es) * 2020-12-03 2023-06-19 Jiangsu Hengrui Pharmaceuticals Co Ltd Composicion farmaceutica de anticuerpo anti-tslp y uso de la misma.
WO2023147784A1 (zh) 2022-02-07 2023-08-10 江苏恒瑞医药股份有限公司 特异性结合psma和cd3的抗原结合分子及其医药用途
MX2024011128A (es) * 2022-03-14 2024-09-18 Jiangsu Hengrui Pharmaceuticals Co Ltd Molecula de union a antigeno que se une especificamente a gprc5d y cd3 y su uso medico.
CN118922449A (zh) * 2022-04-11 2024-11-08 江苏恒瑞医药股份有限公司 特异性结合psma和cd28的抗原结合分子及其医药用途
WO2023198042A1 (zh) * 2022-04-11 2023-10-19 江苏恒瑞医药股份有限公司 特异性结合egfr和cd28的抗原结合分子及其医药用途
KR20250027562A (ko) * 2022-06-23 2025-02-26 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Dll3 및 cd3에 특이적으로 결합하는 항원 결합 분자 및 이의 의약적 용도
WO2024027815A1 (zh) 2022-08-05 2024-02-08 江苏恒瑞医药股份有限公司 特异性结合gucy2c和cd3的抗原结合分子及其医药用途
WO2024131864A1 (zh) * 2022-12-21 2024-06-27 广东菲鹏制药股份有限公司 一种il-10单体融合蛋白
TW202511295A (zh) 2023-08-31 2025-03-16 大陸商江蘇恆瑞醫藥股份有限公司 Ctla4/tigit結合蛋白及其醫藥用途
TW202529809A (zh) * 2023-10-17 2025-08-01 大陸商江蘇恆瑞醫藥股份有限公司 一種抗tslp抗體的醫藥組成物及其用途
AU2024380559A1 (en) 2023-11-17 2026-06-04 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
KR20260115642A (ko) 2023-11-20 2026-07-24 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 재조합 반응을 통해 이종다량체를 제조하는 방법
WO2026061376A1 (zh) * 2024-09-18 2026-03-26 映恩生物科技(上海)有限公司 新型双特异性多肽复合物
WO2026151884A1 (en) 2025-01-09 2026-07-16 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5889151A (en) 1989-10-20 1999-03-30 Societe Leb-Tech Purified human alpha interferon receptor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO2007062037A2 (en) * 2005-11-21 2007-05-31 Laboratoires Serono Sa Compositions and methods of producing hybrid antigen binding molecules and uses thereof
EP1963527A2 (en) 2005-12-15 2008-09-03 Becton, Dickinson and Company, Wagner, Jaconda Diagnosis of sepsis
EP2162459B1 (en) 2007-05-01 2017-10-04 University of Miami Transcriptomic biomarkers for individual risk assessment in new onset heart failure
US9476097B2 (en) * 2011-04-11 2016-10-25 The Brigham And Women's Hospital, Inc. Structural mutations in titin cause dilated cardiomyopathy
US20150183877A1 (en) * 2012-07-18 2015-07-02 Eli Lilly And Company Multi-Specific IgG-(Fab)2 Constructs Containing T-Cell Receptor Constant Domains
KR20150052085A (ko) 2012-09-14 2015-05-13 에프. 호프만-라 로슈 아게 2개 이상의 상이한 단위를 포함하는 분자의 제조 및 선별 방법, 및 이의 용도
WO2015173756A2 (en) * 2014-05-16 2015-11-19 Pfizer Inc. Bispecific antibodies
WO2017106462A1 (en) * 2015-12-18 2017-06-22 Biogen Ma Inc. Bispecific antibody platform
CN117843810A (zh) 2017-09-22 2024-04-09 上海药明生物技术有限公司 新型双特异性多肽复合物
CN109970860A (zh) * 2017-12-27 2019-07-05 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4372001A4 (en) * 2021-07-14 2025-02-12 Jiangsu Hengrui Pharmaceuticals Co., Ltd. ANTIGEN-BINDING MOLECULE SPECIFICALLY BINDING TO HGFR AND EGFR, AND PHARMACEUTICAL USE THEREOF

Also Published As

Publication number Publication date
CN114746440B (zh) 2024-11-15
TWI878430B (zh) 2025-04-01
TW202128770A (zh) 2021-08-01
WO2021139758A1 (zh) 2021-07-15
JP7773981B2 (ja) 2025-11-20
EP4089111A1 (en) 2022-11-16
US20230120270A1 (en) 2023-04-20
CN114746440A (zh) 2022-07-12
AU2021205561A1 (en) 2022-08-11
KR20220123072A (ko) 2022-09-05
EP4089111A4 (en) 2023-10-04
JP2023509212A (ja) 2023-03-07

Similar Documents

Publication Publication Date Title
JP7773981B2 (ja) 新型ポリペプチド複合物
CN107614529B (zh) Pd-l1抗体、其抗原结合片段及其医药用途
CN112625136B (zh) 针对冠状病毒具有中和活性的双特异性抗体及其用途
AU2019243665B2 (en) Multivalent antibody
JP7292200B2 (ja) 抗gprc5d抗体、gprc5dとcd3を結合する二重特異性抗原結合分子、及びその使用
CN110914304B (zh) Cd96抗体、其抗原结合片段及医药用途
JP7538131B2 (ja) 抗cd79b抗体、その抗原結合フラグメントおよびそれらの医薬用途
EP4339213A1 (en) Antigen-binding molecule
US20240141071A1 (en) Antibodies that bind cd123 and gamma-delta t cell receptors
JP2024543134A (ja) 修飾されたタンパク質又はポリペプチド
JP7808306B2 (ja) 抗cd3ヒト化抗体
JP2025526279A (ja) 抗TNFα抗体および組成物
RU2847355C1 (ru) Новый полипептидный комплекс
HK40076302A (en) New polypeptide complex
HK40076302B (en) New polypeptide complex
EP4438624A1 (en) Antibodies that bind nectin-4 and gamma-delta t cell receptors
EA053267B1 (ru) Антигенсвязывающая молекула
HK40106257A (zh) 新型抗sirpa抗体
TW202528360A (zh) 藉由重組反應製備異源多聚體的方法
TW202440645A (zh) 抗muc17*cd3*cd28三特異性抗體
CN121532424A (zh) Btn3a结合蛋白及其医药用途
IL305346A (en) Antibodies that bind cd123 and gamma-delta t cell receptors

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241218

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241218

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241218

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241227

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20241227

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241227

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250110

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250110

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250110

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250110

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250428

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250507

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251222

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251222

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260603